Back to discover
Drug

Efinopegdutide

Early clinical development
ClassGlucagon-like peptide 1 receptor agonist
RxNorm2169690ChEMBLCHEMBL4297576UNIIDR6P1M58PO
2
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 2a Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Different Dosing Regimens of Efinopegdutide (MK-6024) in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease

Clinical trial2026-06-01Results posted · ClinicalTrials.gov

A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic Steatohepatitis

Clinical trial2025-12-29Completed · ClinicalTrials.gov

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Efinopegdutide (MK-6024) in Participants With Moderate and Severe Hepatic Impairment

Clinical trial2025-10-22Results posted · ClinicalTrials.gov

A Single and Multiple-Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Efinopegdutide (MK-6024) in Otherwise Healthy Obese Participants and the Effect of Multiple Doses of Efinopegdutide on the Pharmacokinetics of Acetaminophen

Clinical trial2025-02-18Completed · ClinicalTrials.gov

A Single and Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics of MK-6024 in Healthy Chinese Participants

Clinical trial2023-02-02Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Efinopegdutide
RxNorm CUI
2169690
ChEMBL ID
CHEMBL4297576
UNII
DR6P1M58PO
Primary mechanism
Glucagon-like peptide 1 receptor agonist

Pharmacology & targets

2 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Glucagon-like peptide 1 receptor
GLP1R · P43220
AGONISTGlucagon-like peptide 1 receptor agonist
Glucagon receptor
GCGR · P47871
AGONISTGlucagon receptor agonist

Clinical trials

5 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
5
registered trials across all phases
LATEST COMPLETION 2025
5
Completed
PHASE DISTRIBUTIONn = 5
Phase 13Phase 22

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic Steatohepatitis

CompletedPH IIMerck Sharp & Dohme LLCn=3812025

A Phase 2a Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Different Dosing Regimens of Efinopegdutide (MK-6024) in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease

CompletedPH IIMerck Sharp & Dohme LLCn=1242025

A Single and Multiple-Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Efinopegdutide (MK-6024) in Otherwise Healthy Obese Participants and the Effect of Multiple Doses of Efinopegdutide on the Pharmacokinetics of Acetaminophen

CompletedPH IMerck Sharp & Dohme LLCn=482025

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Efinopegdutide (MK-6024) in Participants With Moderate and Severe Hepatic Impairment

CompletedPH IMerck Sharp & Dohme LLCn=222024

A Single and Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics of MK-6024 in Healthy Chinese Participants

CompletedPH IMerck Sharp & Dohme LLCn=562023
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials